| Sara Caldwell, NP | |
|
744 Middle Creek Rd Ste 108, Sevierville, TN 37862-5036 | |
| (865) 446-9500 | |
| (865) 374-2098 |
| Full Name | Sara Caldwell |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 11 Years |
| Location | 744 Middle Creek Rd Ste 108, Sevierville, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154752145 | NPI | - | NPPES |
| Q057873 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 3008385 (Kentucky) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 27304 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Roane Medical Center | Harriman, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Covenant Medical Group Inc | 2860305463 | 282 |
News Archive
A Cleveland Clinic-led initiative has come up with a new risk scoring system for epileptic or seizure disorders of genetic origin. The researchers summed up the risks for a very large number of genes weakly implicated in some common forms of epilepsy, to create a polygenic risk score.
Men released from prison who receive social, community and spiritual support have better mental health, according to a study by researchers at Rutgers School of Public Health.
Optimer Pharmaceuticals, Inc. announced today the presentation of combined data from its two fidaxomicin Phase 3 trials in patients with Clostridium difficile infection (CDI) at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) in Vancouver, British Columbia, Canada.
Rigel Pharmaceuticals, Inc. today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by AstraZeneca earlier today.
› Verified 2 days ago
| Entity Name | Covenant Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457302010 PECOS PAC ID: 2860305463 Enrollment ID: O20060719000030 |
News Archive
A Cleveland Clinic-led initiative has come up with a new risk scoring system for epileptic or seizure disorders of genetic origin. The researchers summed up the risks for a very large number of genes weakly implicated in some common forms of epilepsy, to create a polygenic risk score.
Men released from prison who receive social, community and spiritual support have better mental health, according to a study by researchers at Rutgers School of Public Health.
Optimer Pharmaceuticals, Inc. announced today the presentation of combined data from its two fidaxomicin Phase 3 trials in patients with Clostridium difficile infection (CDI) at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) in Vancouver, British Columbia, Canada.
Rigel Pharmaceuticals, Inc. today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by AstraZeneca earlier today.
› Verified 2 days ago
| Entity Name | Ipc Pac Healthcare Services Of Tennessee Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104277656 PECOS PAC ID: 0840587572 Enrollment ID: O20160928000541 |
News Archive
A Cleveland Clinic-led initiative has come up with a new risk scoring system for epileptic or seizure disorders of genetic origin. The researchers summed up the risks for a very large number of genes weakly implicated in some common forms of epilepsy, to create a polygenic risk score.
Men released from prison who receive social, community and spiritual support have better mental health, according to a study by researchers at Rutgers School of Public Health.
Optimer Pharmaceuticals, Inc. announced today the presentation of combined data from its two fidaxomicin Phase 3 trials in patients with Clostridium difficile infection (CDI) at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) in Vancouver, British Columbia, Canada.
Rigel Pharmaceuticals, Inc. today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by AstraZeneca earlier today.
› Verified 2 days ago
| Entity Name | Nv Pacs 2 Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427534809 PECOS PAC ID: 0941550578 Enrollment ID: O20210903001263 |
News Archive
A Cleveland Clinic-led initiative has come up with a new risk scoring system for epileptic or seizure disorders of genetic origin. The researchers summed up the risks for a very large number of genes weakly implicated in some common forms of epilepsy, to create a polygenic risk score.
Men released from prison who receive social, community and spiritual support have better mental health, according to a study by researchers at Rutgers School of Public Health.
Optimer Pharmaceuticals, Inc. announced today the presentation of combined data from its two fidaxomicin Phase 3 trials in patients with Clostridium difficile infection (CDI) at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) in Vancouver, British Columbia, Canada.
Rigel Pharmaceuticals, Inc. today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by AstraZeneca earlier today.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sara Caldwell, NP 744 Middle Creek Rd Ste 108, Sevierville, TN 37862-5036 Ph: (865) 446-9500 | Sara Caldwell, NP 744 Middle Creek Rd Ste 108, Sevierville, TN 37862-5036 Ph: (865) 446-9500 |
News Archive
A Cleveland Clinic-led initiative has come up with a new risk scoring system for epileptic or seizure disorders of genetic origin. The researchers summed up the risks for a very large number of genes weakly implicated in some common forms of epilepsy, to create a polygenic risk score.
Men released from prison who receive social, community and spiritual support have better mental health, according to a study by researchers at Rutgers School of Public Health.
Optimer Pharmaceuticals, Inc. announced today the presentation of combined data from its two fidaxomicin Phase 3 trials in patients with Clostridium difficile infection (CDI) at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) in Vancouver, British Columbia, Canada.
Rigel Pharmaceuticals, Inc. today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by AstraZeneca earlier today.
› Verified 2 days ago
Mrs. Maggie Elline Keck, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 415 Catlett Rd, Sevierville, TN 37862 Phone: 865-330-7425 Fax: 865-333-5848 | |
Phyliss A. Shults, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 641 Middle Creek Rd, Sevierville, TN 37862 Phone: 865-428-0583 Fax: 865-428-1625 | |
Meredith Cromer, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1115 Blanton Dr, Sevierville, TN 37862 Phone: 865-453-4434 Fax: 866-610-2903 | |
Jessica Williams Cooper, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 215 Forks Of The River Pkwy, Sevierville, TN 37862 Phone: 865-366-4070 Fax: 865-366-3720 | |
Jordan E Mccroskey, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 675 Middle Creek Rd, Sevierville, TN 37862 Phone: 865-453-2039 Fax: 833-908-2175 | |
Rhonda Levada Daniels-reinalda, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1787 Veterans Blvd Ste 101, Sevierville, TN 37862 Phone: 865-428-2773 | |
Mrs. Jessica Breedlove, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 470 Collier Dr, Sevierville, TN 37862 Phone: 865-286-5421 |